By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced it has renewed its microfluidic chip supply agreement with Agilent Technologies.

Under a new seven-year agreement, Caliper will remain the exclusive supplier of microfluidic chips to Agilent for use on its Bioanalyzer 2100 platforms. Since its launch in 1999, more than 7,000 Bioanalyzer 2100 instruments have been sold, and Caliper has supplied about 5 million chips for use on the platform, Caliper said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.